DOCSLIB.ORG

Post Marketing Safety Data Analysis Reveals Increased Propensity For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Post Marketing Safety Data Analysis Reveals Increased Propensity For Post Marketing Safety Data Analysis Reveals Increased Propensity for Severe Cardiovascular and Cerebrovascular Side Effects in Patients Taking Celecoxib Compared to Other NSAIDs Aarti Patel, PharmD Candidate, Tigran Makunts, PharmD, Ruben Abagyan, Ph.D. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA ABSTRACT RESULTS Non-steroidal anti-inflammatory medications, NSAIDS, are commonly used Cardiovascular ADR Report Frequencies Cardiovascular ADR Report Frequencies Odds ratios of cardiovascular ADR worldwide for their analgesic and anti-inflammatory properties, and are deemed out of 100,202 NSAID Reports Among Male and Female Celecoxib Users among Celecoxib male users when safe for over the counter access. NSAIDS as a class have been associated with Myocardial Infarction 4.79 compared to female users cardiovascular, CV, cerebrovascular, CVA, and hypertension, side effects, with Cerebrovascular Accident 3.66 Cerebrovascular 9.69 Accident 11.23 rofecoxib being removed from the market due to these toxicities. However, the Chest Pain 0.85 Cerebrovascular Accident 1.18 risks of heart attack and stroke were deemed similar in all currently marketed Hypertension 0.73 Palpitations 0.49 1.77 NSAIDs. The growing concern over the potentially fatal CV and CVA warranted ADR Hypertension Hypertension 1.16 Hypotension 0.46 ADR 2.05 FEMALES further studies to quantify the associations these side effects. Here, we ADR Atrial Fibrillation MALES analyzed over twelve million reports in the FDA Adverse Event Reporting 0.29 Congestive Heart Failure 0.28 12.16 System, FAERS, to evaluate the reporting odds ratios of hypertension, Myocardial Infarction Myocardial Infarction 2.42 Tachycardia 0.25 myocardial infarction, and stroke in patients taking individual NSAIDs and 25.11 0 1 2 3 4 5 acetaminophen as monotherapy. We found that the risk of CV and CVA ADRs 0 0.5 1 1.5 2 2.5 3 FREQUENCY (%) 0 5 10 15 20 25 30 ROR was 10-200 fold higher for celecoxib, when compared to ibuprofen, naproxen, FREQUENCY (%) meloxicam, ketoprofen, diclofenac and acetaminophen. Additionally, male Fig. 1. Top Cardiovascular ADRs in patients taking NSAIDs for pain Fig. 3. Celecoxib ADRs among male and female users. a) Frequencies of CVA, HTN, and MI patients taking celecoxib were at a nearly two-fold higher risk of myocardial were calculated between male and female Celecoxib users. b) Odds ratios were performed among infarction. Odds ratios of myocardial infarction reports of male users when compared to females for the three ADRs. Celecoxib when compared to other NSAIDs Fig. 2. Odds ratios of Celecoxib vs Acetaminophen 34.22 BACKGROUND AND PURPOSE cardiovascular ADRs. Odds CONCLUSIONS ratios were calculated by Celecoxib vs Ketorolac 11.53 comparing MI, HTN, and stroke Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely Overall, our results revealed that NSAIDs had a significantly higher risk of Celecoxib vs Diclofenac 22.36 ADRs of Celecoxib to other prescribed drugs worldwide. They are used by over thirty million people daily NSAID pain medications. cardiovascular adverse effects when compared to non-NSAID pain 1 Celecoxib vs Naproxen 28.726 medications. Out of these NSAID medications, Celecoxib exhibited the highest seeking their anti-inflammatory and pain relieving properties . They work by NSAIDs rates of MI, HTN, and CVA adverse effects. In addition, male Celecoxib users selectively inhibiting the cyclooxygenase (COX) enzymes, of which there are Celecoxib vs Ibuprofen 198.58 two isoforms. COX-1 plays a protective role and is present in many tissues, had a higher risk of all three of these adverse effects when compared to female maintaining platelet activity, kidney functions, and protection of stomach Celecoxib vs Meloxicam 10.28 users, the highest being myocardial infarction. The FDA has released and 3 mucosa . On the other hand, COX-2 is present at sites of inflammation. In 1 10 100 1000 changed the Celecoxib label slightly over the past few years after adding a recent years, NSAIDs have come into the light due to their serious, life- ROR BBW 2007, a black box warning was added to the label to warn consumers threatening adverse effects, particularly the negative cardiovascular effects. about the potential cardiovascular risks associated with Celecoxib use while Odds ratios of hypertension reports of Celecoxib stating that “all NSAIDs may have a similar risk.” However, in 2016, the black Randomized clinical trials were performed and found an increased risk of when compared to other NSAIDs stroke, MI, and HTN associated with particularly celecoxib use. This promoted box warning was slightly altered, reporting that “based on available data, it is the FDA to include a black box warning in 2007. To date, the relationship Celecoxib vs Acetaminophen 1.1352 unclear that the risk for CV thrombotic events is similar for all NSAIDs. Our between NSAID and non-NSAID use and its effects on heart attack, stroke, and study has demonstrated that the CV risk for all NSAID pain medications is not Celecoxib vs Ketorolac 1.436 hypertension remains largely unclear and warrants further research. The similar and that Celecoxib has a significantly higher risk when compared to the previous studies showed conflicting evidence, which warrants further studies of Celecoxib vs Diclofenac 1.8887 other more commonly prescribed NSAIDs. Finally, this study aimed to provide post marketing ADR reports. It was necessary to expand on the evidence and more clarity to the FDA drug label put forth on Celecoxib and its potentially life- Celecoxib vs Naproxen 2.2552 introduce clarity on potentially fatal ADRs of these commonly used medications. NSAIDs threatening adverse effects. It highlights the necessity of exercising caution In this study, we analyzed 120,707 FAERS database reports to analyze the Celecoxib vs Ibuprofen 2.69 while prescribing this medication and also urges consumers to use Celecoxib relationship between NSAID use and cardiovascular adverse effects, namely for the shortest duration possible, or perhaps even use other NSAIDs which Celecoxib vs Meloxicam 1.5442 hypertension (HTN), cerebrovascular accident (CVA), and myocardial infarction have been well studied and have fewer known adverse effects. (MI). 0 0.5 1 1.5 2 2.5 3 3.5 ROR REFERENCES Odds ratios of cerebrovascular accident reports METHODS 1. Wongrakpanich, S., Wongrakpanich, A., Melhado, K. & Rangaswami, J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging and Disease of Celecoxib when compared to other NSAIDs 9,143–150 (2018). 2. Gaikwad, N., Vaishnavi, P. R. & Dhaneria, S. Assessment of nonsteroidal anti-inflammatory drug use pattern using world health organization indicators: A cross-sectional study in a tertiary care teaching hospital of Chhattisgarh. Indian Journal of Pharmacology 49,445–450 (2017). In this study, 102,702 reports were selected. Patients 18 years of age and older 3. Bavry, A. & Park, K. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vascular Health and Risk Management 25-30 (2014). doi:10.2147/vhrm.s54159 Celecoxib vs Acetaminophen 60.7177 4. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. August 2017. doi:10.7759/cureus.1144. taking the following NSAIDs, ibuprofen, meloxicam, celecoxib, diclofenac, ketorolac, 5. Fries, S. The Cardiovascular Pharmacology of COX-2 Inhibition. Hematology 2005,445–451 (2005). Celecoxib vs Ketorolac 27.69 6. Whelton, A., White, W. B., Bello, A. E., Puma, J. A. & Fort, J. G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic and non-NSAID medication, acetaminophen, as monotherapy were selected into hypertension and osteoarthritis. The American Journal of Cardiology 90,959–963 (2002). 7. Solomon, S. D. et al.Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials. Circulation 117,2104–2113 (2008). cohorts. Patients with heart conditions such as coronary artery disease were Celecoxib vs Diclofenac 8. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet 382,769–779 10.605 (2013). 9. Baselyous, Y. et al.Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event excluded. The NSAID group contained 100,202 reports and the non-NSAID group Expert Opinion on Drug Safety Celecoxib vs Naproxen 12.59 reports from Australia, Canada and the USA. 18,153–161 (2019). contained 20,700 reports. CV and CVA adverse drug events frequencies were NSAIDs calculated: celecoxib n=20,614, meloxicam n=1753, ibuprofen n=27,037, naproxen Celecoxib vs Ibuprofen 214.727 n=34,644, diclofenac n=14,866, ketorolac n=1288, and acetaminophen n=20,700. ACKNOWLEDGEMENTS Frequencies of MI, HTN, and CVA were reported for NSAIDs and compared to non- Celecoxib vs Meloxicam 21.7685 This work was supported by a Skaggs Scholarship from the UC San Diego NSAID pain medications (Fig. 1). We also analyzed male and female reports of CV 1 10 100 1000 Skaggs School of Pharmacy and Pharmaceutical Sciences adverse events among Celecoxib users (Fig. 3). ROR.
Load more

Recommended publications
  • Meloxicam 15 Mg Orodispersible Tablets Meloxicam 15.0 Mg
    PACKAGE LEAFLET: INFORMATION FOR THE USER Meloxicam 15 mg Orodispersible Tablets Meloxicam 15.0 mg Read all of this leaflet carefully before you start taking may occur if you have serious blood loss or burns, surgery or low this medicine. fluid intake; Keep this leaflet. You may need to read it again. if you have ever been diagnosed with high potassium levels in If you have any further questions, please ask your doctor or the blood; pharmacist. Tell your doctor if you think any of these apply to you. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are Warning the same as yours. Medicines such as these Meloxicam tablets may be If any of the side effects become serious, or if you notice associated with a small increased risk of heart attack or any side effects not listed in this leaflet, please tell your doctor or stroke. Any risk is more likely with high doses and prolonged pharmacist. treatment. Do not exceed the recommended dose or duration of treatment. IN THIS LEAFLET: Discuss your treatment with your doctor or pharmacist if you have heart problems, have previously had a stroke or you think you 1. What Meloxicam orodispersible tablets are and what might be at risk of conditions such as high blood pressure, they are used for diabetes or high cholesterol, or if you are a smoker. 2 . Before you take Meloxicam tablets 3. How to take Meloxicam tablets Taking other medicines When you are taking Meloxicam tablets, do not take any other 4.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Mobic Tablets Meloxicam Consumer Medicine Information
    Mobic Tablets meloxicam Consumer Medicine Information What is in this leaflet Although Mobic can relieve the bypass graft or major vascular symptoms of pain and inflammation, surgery This leaflet answers some common it will not cure your condition. Mobic • have a disease of the heart with questions about Mobic. belongs to a family of medicines shortness of breath, and swelling called Non-Steroidal Anti- of the feet or lips due to fluid It does not contain all the available Inflammatory Drugs (NSAIDs). information. build-up These medicines work by relieving • experience bleeding from the It does not take the place of talking to pain and inflammation. your doctor or pharmacist. stomach, gut or any other Ask your doctor if you have any bleeding All medicines have risks and questions about why this medicine • benefits. Your doctor has weighed has been prescribed for you. had a stroke resulting from a the risks of you taking Mobic against bleed in the brain or have a Your doctor may have prescribed it bleeding disorder the benefits they expect it will have for another reason. for you. • had a heart attack This medicine is available only with • If you have any concerns about a doctor's prescription. have galactose intolerance taking this medicine, ask your • are pregnant or intend to become doctor or pharmacist. pregnant This leaflet was last updated on the • have a peptic (stomach) ulcer date at the end of this leaflet. More Before you take Mobic • have or have had inflammation of recent information may be available. the lining of the stomach or The latest Consumer Medicine When you must not take it Information is available from your bowel (e.g.
    [Show full text]
  • Motrin® Ibuprofen Tablets, USP
    Effective Date: 01/20/2007 Motrin® Ibuprofen Tablets, USP Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). • MOTRIN tablets are contraindicated for treatment of peri- operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). DESCRIPTION MOTRIN tablets contain the active ingredient ibuprofen, which is (±) - 2 - (p - isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting point of 74-77° C and is very slightly soluble in water (<1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula is represented below: MOTRIN tablets, a nonsteroidal anti-inflammatory drug (NSAID), is available in 400 mg, 600 mg, and 800 mg tablets for oral administration. Inactive ingredients: carnauba wax, colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, titanium
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Non-Selective Oral Nonsteroidal Anti-Inflammatory Drugs AHFS Classification: 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents Diclofenac Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Ketoprofen Ketorolac Mefenamic Acid Meloxicam Nabumetone Naproxen Oxaprozin Piroxicam Sulindac Tolmetin Final Report April 2018 Review prepared by: Elena Martinez Alonso, B.Pharm., Medical Writer Vicki Frydrych, B.Pharm., Pharm.D., Clinical Pharmacist Valerie Gonzales, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor, Clinical Pharmacist Michelle Fiander, MA, MLIS, Research Assistant Professor, Evidence Synthesis Librarian Joanne LaFleur, PharmD, MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved 1 Contents Executive Summary ...................................................................................................................................... 3 Introduction ................................................................................................................................................... 6 Table 1. FDA-Approved Oral Non-selective NSAIDs......................................................................... 7 Table 2. FDA-Approved Indication for Oral Non-selective NSAIDs ...............................................
    [Show full text]
  • Single Dose of Diclofenac Or Meloxicam for Control of Pain, Facial Swelling, and Trismus in Oral Surgery
    Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e127-34. Diclofenac versus meloxicam in oral surgery Journal section: Oral Surgery doi:10.4317/medoral.20925 Publication Types: Research http://dx.doi.org/doi:10.4317/medoral.20925 Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery Mariana Orozco-Solís 1, Yazmín García-Ávalos 2, Celeste Pichardo-Ramírez 2, Francisco Tobías-Azúa 2, Juan-Ramón Zapata-Morales 3, Othoniel-Hugo Aragon-Martínez 4, Mario-Alberto Isiordia-Espinoza 5 1 DDS, Departamento de Estomatología, Unidad Médica Familiar No. 02, Instituto Mexicano del Seguro Social, Delegación San Luis Potosí, S.L.P., México 2 DDS, Departamento de Investigación y Postgrado, Escuela de Odontología, Universidad Cuauhtémoc, plantel San Luis Poto- sí, S.L.P., México 3 MSc, PhD, Departamento de Farmacia, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Guanajuato, México 4 MSc, PhD, Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, S.L.P., México 5 DDS, MSc, PhD, Departamento de Farmacología, Facultad de Odontología, Universidad Autónoma de Baja California, Mexi- cali, México Orozco-Solís M, García-Ávalos Y, Pichardo-Ramírez C, Tobías-Azúa F, Zapata-Morales JR, Aragon-Martínez OH, Isiordia-Espinoza MA. Single Correspondence: dose of diclofenac or meloxicam for control of pain, facial swelling, and Facultad de Odontología trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 Universidad Autónoma de Baja California (1):e127-34. Calle Zotoluca y Chinampas s/n http://www.medicinaoral.com/medoralfree01/v21i1/medoralv21i1p127.pdf Fraccionamiento Calafia C.P.
    [Show full text]
  • How Does Meloxicam (Mobicox?) Compare to Other Nsaids and Csis
    The Rx Files: Q&A Summary February 2001 â Update on Meloxicam (Mobicoxâ) & COX-2 Selectivity COX-2 Selectivity/Specificity adverse GI events.10 This data must be cautiously interpreted wThere is a lot of discussion regarding the relative COX-2 due to the inherent limitations of the meta-analysis, such as selectivity of meloxicam compared to celecoxib (Celebrexâ) variability of trial outcomes, and the low dosage of meloxicam and rofecoxib (Vioxxâ). A December 2000 RxFiles Q&A used in most trials. Summary regarding meloxicam stated that it had “relatively wMeloxicam appears to have better GI tolerance than non- selective but not specific COX-2 inhibition” as discussed in selective NSAIDs. To what extent ulcers and complicated a variety of literature.1,2,3,4,5 Boehringer Ingelheim (Canada) ulcers are also reduced remains to be established. Ltd. (BICL) has been detailing meloxicam as an agent with wMajor trials evaluating the safety of the other COX-2 selective COX-2 selectivity comparable to celecoxib based on data drugs, celecoxib (Celebrexâ) and rofecoxib (Vioxxâ) have been from BICL sponsored work of Warner et al.6 This research published. These trials differ from the large-scale meloxicam measured NSAID inhibition of COX-1 when COX-2 trials as dosages were 2-4X higher than usually enzyme activity is inhibited by 80%. It found that both recommended and trial length was longer (see Table). meloxicam and celecoxib were 5-50 fold selective for COX- §The CLASS11 study compared celecoxib to non-selective 2, with rofecoxib being >50 fold COX-2 selective. The NSAIDs (ibuprofen and diclofenac).
    [Show full text]
  • Tolfenamic Acid and Meloxicam Both Provide an Adequate Degree of Postoperative Analgesia in Dogs Undergoing Ovariohysterectomy
    Veterinarni Medicina, 62, 2017 (06): 333–341 Original Paper doi: 10.17221/143/2016-VETMED Tolfenamic acid and meloxicam both provide an adequate degree of postoperative analgesia in dogs undergoing ovariohysterectomy X.Y. Hu, L. Luan, W. Guan, J. Shi, Y.B. Zhao, H.G. Fan* Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China *Corresponding author: [email protected] ABSTRACT: This study was aimed at comparing the postoperative analgesic effects of tolfenamic acid and meloxi- cam in dogs undergoing ovariohysterectomy. Ovariohysterectomy was performed in 24 female dogs. All dogs were administered pre-anaesthetic medication comprised of 0.02 mg/kg i.m. acepromazine, and general anaesthesia was induced with i.v. propofol (4–6 mg/kg) and maintained with 1.5–2.0% isoflurane. Dogs were divided into three groups (n = 8). Following induction of anaesthesia, group C received 0.05 ml/kg sterile saline i.m.; group T received 4 mg/kg tolfenamic acid i.m.; group M received 0.2 mg/kg meloxicam s.c. Heart rate, respiratory rate, rectal tem- perature, mean arterial pressure and arterial oxygen saturation of haemoglobin were monitored intraoperatively. Pain was assessed using the short form of the Glasgow composite pain scale (SF-GCPS) by two observers who were blinded to the treatment groups; pain was assessed at the time of pre-medication (baseline), and at 2, 4, 6, 8, 12 and 24 h after extubation. Rescue analgesia (0.2 mg/kg i.m. methadone) was administered to any dog with an SF-GCPS score of greater than or equal to six during postoperative monitoring.
    [Show full text]
  • Nsaids in Cats
    ISFM and AAFP Consensus Guidelines Long-term use of NSAIDs in cats Clinical Practice A preprint from the Journal of Feline Medicine and Surgery Volume 12, July 2010 Journal of Feline Medicine and Surgery (2010) 12, 519 doi:10.1016/j.jfms.2010.05.003 EDITORIAL NSAIDs and cats – it’s been a long journey Although the first This issue of JFMS contains the first ever panel have covered much valuable ground: international consensus guidelines ✜ To set the scene they consider how use of NSAIDs on the long-term use of non-steroidal common chronic pain can be in cats, typically was probably anti-inflammatory drugs (NSAIDs) in cats. related to degenerative joint disease, This timely publication, which appears on idiopathic cystitis, trauma and cancer. by Hippocrates, pages 521–538 (doi:10.1016/j.jfms.2010.05.004), ✜ They then explain how and why NSAIDs is a collaborative enterprise by the International can have such positive and, potentially, it has taken until Society of Feline Medicine (ISFM) and negative actions. now for cats to American Association of Feline Practitioners ✜ They consider the best ways of enhancing (AAFP). It has been compiled by a panel of owner and cat compliance, make suggestions gain the benefit of world leaders in the understanding of pain about sensible dosing frequencies, timing of in cats and, without doubt, is essential reading medication and accuracy of dosing, and the long-term use for all small animal veterinary surgeons. emphasize the importance of always using of these drugs. It is interesting to reflect that although the ‘lowest effective dose’.
    [Show full text]
  • Indocin® (Indomethacin) Oral Suspension
    INDOCIN® (INDOMETHACIN) ORAL SUSPENSION Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at a greater risk. (See WARNINGS.) • INDOCIN is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Suspension INDOCIN1 for oral use contains 25 mg of indomethacin per 5 mL, alcohol 1%, and sorbic acid 0.1% added as a preservative and the following inactive ingredients: antifoam AF emulsion, flavors, purified water, sodium hydroxide or hydrochloric acid to adjust pH, sorbitol solution, and tragacanth. Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. 1 Indomethacin is practically insoluble in water and sparingly soluble in alcohol. It has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali. The suspension has a pH of 4.0-5.0. The structural formula is: 1 Registered trademark of MERCK & CO., Inc., Whitehouse Station, NJ U.S.A. and licensed to Iroko Pharmaceuticals, LLC, Philadelphia, PA, U.S.A.
    [Show full text]
  • Plantar Fasciitis - Managing the Symptoms and Promoting Healing
    PLANTAR FASCIITIS - MANAGING THE SYMPTOMS AND PROMOTING HEALING Plantar fasciitis occurs when the fascia develops pain and inflammation. It may happen from a forceful pull on the fascia causing severe heel pain or from prolonged standing putting excessive pressure over the fascia. The plantar fascia has low blood flow, so it may have a hard time getting the nutrients it needs to heal and can take up to 3 months to fully heal. Unfortunately, the low blood flow can frequently lead to chronic symptoms, in which the plantar fascia fibers in it degenerate and weaken, leading to chronic pain and weakness. 1. Weight Management: The #1 cause of plantar fasciitis is being overweight a. For every 1 lb of weight, we put 4 lbs of pressure in our lower body joints b. Goal is to have a BMI under 25. To achieve this, lose 1 lb per week with diet and exercise 2. Diet & Supplements: They are the natural way of decreasing pain and inflammation a. Anti-inflammatory Diet (ex. Dr Andrew Weil’s diet) i. Eat whole fruits and vegetables, whole grains and nuts, lean meats (Ex. Fish, turkey, etc.) ii. Avoid processed carbohydrates, white bread, sugar, sodas, saturated fat, and fried foods b. Herbs and spices (ex. Turmeric, Bromelain, garlic, cherry tart, etc. per bottle directions) 3. Physical Therapy (PT): “Movement is medicine”. PT will help you restore your strength, stretch the fascia, decrease inflammation and transition to a home program. a. Range of motion – Restore proper biomechanics to promote healing and prevent re-injury. b. Strength & conditioning – Promotes healing of the fascia.
    [Show full text]